Books/Chapters
Clairmont AC, Elsheikh B, Mohammad YM. “Evaluation of the patient with suspected myopathy.” in Johnson’s Practical Electromyography, by Pease WS, Lew HL, Johnson E. Philadelphia PA: Lippincott Williams & Wilkins. 2006
Elsheikh B, Freimer ML. ”Peripheral neuropathy.” in Principles and practice of geriatric medicine. Pages 889-898, West Sussex England: John Wiley & Sons Limited, 2006.
Journals
Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, Mendell JR. Pilot trial of etanercept in the treatment of inclusion body myositis. Neurology 2006;66:S123-4.
Biegler BW, Yan SX, Ortega SB, Tennakoon DK, Racke MK, Karandikar NJ. Glatiramer acetate therapy induces a focused, oligoclonal CD8+ T-cell repertoire in multiple sclerosis. J Neuroimmunol 2006;180:159-171.
Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 2006;67:400-406.
Bourekas EC, Figg GM, Slone W, Newton HB. Incidence and complication rate of incidental aneurysms discovered during intra-arterial chemotherapy of brain tumors. AJNR 2006;27:297-299.
Caballero J, Hitchcock M, Beversdorf D, Scharre D, Nathata M. Long term effects of antidepressants on cognition in patients with Alzheimer’s disease. J Clin Pharm Ther 2006;31:1-6.
Caballero J, Hitchcock M, Scharre D, Beversdorf D, Nahata MC. Cognitive effects of atypical antipsychotics in patients with Alzheimer’s disease and comorbid psychiatric or behavioral problems: A retrospective study. Clin Ther 2006;28:1695-1700.
Cavaliere R, Newton HB. Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future. Expert Opin Pharmacother 2006;7:749-765.
Cummings JL, Arciniegas DB, Brooks BR, Herndon RM, Lauterbach EC, Pioro EP, Robinson RG, Scharre DW, Schiffer RB, Weintraub D. Defining and diagnosing involuntary emotional expression disorder (IEED). CNS Spectr 2006;11(suppl 6):1-7.
Drew PD, Xu J, Storer PD, Chavis JA, Racke MK. Peroxisome proliferator-activated receptor agonist regulation of glial activation: Relevance to CNS inflammatory disorders. Neurochem Int 2006;49: 183-189.
Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine J, Cutter G, Richert J, Filippi M. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol 2006;63:614-619.
Frohman EM. Racke MK, Raine CS. Multiple sclerosis: The plaque and its pathogenesis. New Engl J Med 2006;354:942-955.
Christoforidis GA, Mohammad Y, Avutu B, Tejada A, Slivka AP. Arteriographic demonstration of slow antegrade opacification distal to a cerebrovascular thromboembolic occlusion site as a favorable indicator for intra-arterial thrombolysis AJNR 2006;27:1528-1531.
Hansen BS, Hussain RZ, Lovett-Racke AE, Thomas JA, Racke MK. Multiple toll-like receptor agonists act as potent adjuvants in the induction of autoimmunity. J Neuroimmunol 2006;172:94-103.
Kitzmiller J, Beversdorf D, Hansford D. Fabrication and testing of microelectrodes for small-field cortical surface recordings. Biomed Microdevices 2006;8:81-85.
Kostyk SK, Frederick J, Marshall, MD. Tetrabenazine as antichorea therapy in Huntington Disease: A randomized controlled trial. Neurology 2006;66:366-372.
Lovett-Racke AE, Racke MK. Epstein-Barr virus and multiple sclerosis. Arch Neurol 2006;63:810-811.
Lynn DJ. Continuum, CME publication of the American Academy of Neurology: Feb 2006 issue on Critical Care Neurology, Oct 2006 issue on Psychiatry for Neurologists
Mohammad YM, Kasner S, Chimowitz M, Lynn M, et al. for the WASID Investigators. Predictors of ischemic stroke in the territory of a symptomatic intracranial stenosis. Circulation 2006;113:555-563.
Mohammad YM. Low use of t-PA for acute ischemic stroke nationwide: a wake-up call. Comment on Qureshi AI et al. Thrombolysis for ischemic stroke in the United States. Journal Watch Neurology, March 2006.
Mohammad YM. Quantitation of regional cerebral blood flow: the next chapter in digital subtraction angiography. Journal of Neuroimaging 2006 Apr;16(2):179-180.
Moore SA, Shilling CJ, Westra S, Wall C, Wicklund MP, Stolle C, Brown CA, Michele DE, Piccolo F, Winder TL, Stence A, Barresi R, King N, King W, Florence J, Campbell KP, Fenichel GM, Stedman HH, Kissel JT, Griggs RC, Pandya S, Mathews KD, Pestronk A, Serrano C, Darvish D, Mendell JR. Limb-girdle muscular dystrophy in the USA. J Neuropathol Exp Neurol 2006 Oct;65(10):995-1003.
Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, Mendell JR. Pilot trial of etanercept in the treatment of inclusion body myositis. Neurology 2006 Jan 24;66 (2 Suppl 1):S123-4.
Moore SA, Shilling CJ, Westra S, Wall C, Wicklund MP, Stolle C, Brown CA, Michele DE, Piccolo F, Winder TL, Stence A, Barresi R, King N, King W, Florence J, Campbell KP, Fenichel GM, Stedman HH, Kissel JT, Griggs RC, Pandya S, Mathews KD, Pestronk A, Serrano C, Darvish D,Mendell JR. Limb-girdle muscular dystrophy in the USA. Journal of Exp Neurol 2006 Oct;65(10):995-1003.
Newton HB. Advances in strategies to improve drug delivery to brain tumors. Expert Rev Neurother 2006;6:1495-1509.
Newton HB, Chaudhury AR, Cavaliere R. Brain tumor imaging and cancer management. The neuro-oncologists perspective. Top Magnetic Reson Imag 2006;17:127-136.
Newton HB, Figg GM, Slone W, Bourekas E. Incidence of infusion plan alterations after angiography in patients undergoing intra-arterial chemotherapy for brain tumors. J Neuro-Oncol 2006;78:157-160.
Newton HB, Goldlust S, Pearl D. Retrospective analysis of the efficacy and tolerability oflevetiracetam in brain tumor patients. J Neuro-Oncol 2006;78:99-102.
Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, McDonald S, for the Memantine MEM-MD-10 Study Group including Scharre D. Memantine treatment in mild to moderate Alzheimer’s disease: A 24-week randomized controlled trial. Am J Geriatr Psychiatry 2006;14:704-715
Racke MK, Gocke AR, Muir M, Diab A, Drew PD, Lovett-Racke AE. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J Nutrition 2006;136: 700-703.
Ratts RB, Lovett-Racke AE, Choy J, Northrop SC, Hussain RZ, Karandikar NJ, Racke MK. CD28-CD57+ T cells predominate in CD8 responses to glatiramer acetate. J Neuroimmunol 2006;178:117-129.
Ratts RB, Karandikar NJ, Hussain RZ, Choy J, Northrop SC, Lovett-Racke AE, Racke MK. Phenotypic characterization of autoreactive T cells in multiple sclerosis. J Neuroimmunol 2006;178: 100-110.
Slivka AP, Notestine MA, Li J, Christoforidis GA. Clinical predictors of cerebrovascular occlusion for patients presenting with acute stroke. J Stroke and Cerebrovasc Dis 2006;15:30-33.
Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK. Altered CD4:CD8 T cell ratios in cerebrospinal fluid of natalizumab-treated multiple slerosis ptients. Archives of Neurology 2006;23:1383-1387.
Stüve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Hemmer B, Monson NL, Racke MK. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747.
Scharre DW. Galantamine with adjunctive memantine: combined effects on brain nicotinic acetylcholine receptors and N-methyl-D-aspartate (NMDA) receptors may improve Alzheimer’s disease symptomatology. J Clin Pharmacol 2006;46:6S-7S.
Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, Karandikar NJ. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol 2006;176:7119-7129.
Xu J, Chavis JA, Racke MK, Drew PD. Peroxisome proliferator-activated receptor- and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 2006;176:95-105.